Kymera Therapeutics Share Price (NASDAQ: KYMR)

$41.2

▲

-0.55

(-1.32%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Kymera Therapeutics Stock chart to analyse performance

Kymera Therapeutics stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$41.04
Today's High:$42.02
$41.20
0.39%
Downside
Day's Volatility :2.33%
Upside
1.95%
52 Weeks Low:$19.45
52 Weeks High:$53.27
$41.20
52.8%
Downside
52 Weeks Volatility :63.5%
Upside
22.66%

Kymera Therapeutics Stock Returns

Period	Kymera Therapeutics Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-4.51%	3.6%	0.0%
6 Months	36.51%	-7.7%	0.0%
1 Year	-11.09%	-12.6%	0.0%
3 Years	46.62%	9.5%	-4.7%

Kymera Therapeutics Inc Key Stats

Check Kymera Therapeutics key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$41.75
Open	$42.03
Today's High	$42.02
Today's Low	$41.04
Market Capitalization	$3.0B
Today's Volume	$596.3K
52 Week High	$53.27
52 Week Low	$19.445
Revenue TTM	$44.7M
EBITDA	$-305.1M
Earnings Per Share (EPS)	$-3.49
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-33.26%

Stock Returns calculator for Kymera Therapeutics Stock including INR - Dollar returns

The Kymera Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Kymera Therapeutics investment value today

Current value as on today

₹90,478

Returns

₹9,522

(-9.52%)

Returns from Kymera Therapeutics Stock

₹14,806 (-14.81%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Kymera Therapeutics Stock

17%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Kymera Therapeutics Stock from India on INDmoney has increased by 17% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Kymera Therapeutics Inc

Name
Holdings %
Name
Holdings %
T. Rowe Price Associates, Inc.
9.72%
Baker Bros Advisors LP
9.43%
venBio Select Advisor LLC
9.29%
Vanguard Group Inc
7.96%
Bvf Inc
7.80%
Wellington Management Company LLP
7.61%

Analyst Recommendation on Kymera Therapeutics Stock

Rating

Trend

Buy

69%Buy

30%Hold

0%Sell

Based on 23 Wall street analysts offering stock ratings for Kymera Therapeutics(by analysts ranked 0 to 5 stars)

Kymera Therapeutics Share Price Target

What analysts predicted

Upside of 46.53%

Target:

$60.37

Current:

$41.20

Kymera Therapeutics share price target is $60.37, a slight Upside of 46.53% compared to current price of $41.20 as per analysts' prediction.

Kymera Therapeutics Stock Insights

Price Movement
In the last 7 days, KYMR stock has moved down by -6.6%
Decreasing Revenue
Revenue is down for the last 2 quarters, 22.1M → 11.47M (in $), with an average decrease of 48.1% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -65.58M → -76.61M (in $), with an average decrease of 16.8% per quarter
KYMR vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.9% return, outperforming this stock by 84.7%
KYMR vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 112.6% return, outperforming this stock by 66.1%
Price to Sales
ForKYMR every $1 of sales, investors are willing to pay $73.0, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.5 for every $1 of sales.

Kymera Therapeutics Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$2.9M	-
Net Income	$-41.3M	↑ 92.35%
Net Profit Margin	-1.4K%	-

	FY20	Y/Y Change
Revenue	$34.0M	↑ 1059.99%
Net Income	$-43.9M	↑ 6.42%
Net Profit Margin	-129.12%	↑ 1278.24%

	FY21	Y/Y Change
Revenue	$72.8M	↑ 114.0%
Net Income	$-98.0M	↑ 122.99%
Net Profit Margin	-134.55%	↓ 5.43%

	FY22	Y/Y Change
Revenue	$46.8M	↓ 35.71%
Net Income	$-151.8M	↑ 54.94%
Net Profit Margin	-324.25%	↓ 189.7%

	FY23	Y/Y Change
Revenue	$78.6M	↑ 67.84%
Net Income	$-147.0M	↓ 3.21%
Net Profit Margin	-186.99%	↑ 137.26%

	FY24	Y/Y Change
Revenue	$47.1M	↓ 40.11%
Net Income	$-223.9M	↑ 52.32%
Net Profit Margin	-475.57%	↓ 288.58%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$10.3M	↓ 78.52%
Net Income	$-48.6M	↑ 237.95%
Net Profit Margin	-472.02%	↓ 442.01%

	Q2 FY24	Q/Q Change
Revenue	$25.7M	↑ 149.34%
Net Income	$-42.1M	↓ 13.38%
Net Profit Margin	-163.98%	↑ 308.04%

	Q3 FY24	Q/Q Change
Revenue	$3.7M	↓ 85.42%
Net Income	$-62.5M	↑ 48.56%
Net Profit Margin	-1.7K%	↓ 1506.35%

	Q4 FY24	Q/Q Change
Revenue	$7.4M	↑ 97.65%
Net Income	$-70.8M	↑ 13.23%
Net Profit Margin	-956.88%	↑ 713.45%

	Q1 FY25	Q/Q Change
Revenue	$22.1M	↑ 198.89%
Net Income	$-65.6M	↓ 7.31%
Net Profit Margin	-296.75%	↑ 660.13%

	Q2 FY25	Q/Q Change
Revenue	$11.5M	↓ 48.07%
Net Income	$-76.6M	↑ 16.82%
Net Profit Margin	-667.6%	↓ 370.85%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$2.1M	↓ 1128.78%

	FY20	Y/Y Change
Profit	$-28.1M	↓ 1431.01%

	FY21	Y/Y Change
Profit	$70.4M	↓ 350.92%

	FY22	Y/Y Change
Profit	$43.8M	↓ 37.75%

	FY23	Y/Y Change
Profit	$78.6M	↑ 79.23%

	FY24	Y/Y Change
Profit	$47.1M	↓ 40.11%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$10.3M	↓ 78.52%

	Q2 FY24	Q/Q Change
Profit	$25.7M	↑ 149.34%

	Q3 FY24	Q/Q Change
Profit	$3.7M	↓ 85.42%

	Q4 FY24	Q/Q Change
Profit	$7.4M	↑ 97.65%

	Q1 FY25	Q/Q Change
Profit	$22.1M	↑ 198.89%

	Q2 FY25	Q/Q Change
Profit	$9.4M	↓ 57.5%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$17.9M	↓ 200.24%
Investing Cash Flow	$-16.5M	↑ 1115.78%
Financing Cash Flow	$34.9M	↓ 34.05%

	FY20	Y/Y Change
Operating Cash Flow	$88.1M	↑ 392.21%
Investing Cash Flow	$-422.6M	↑ 2463.31%
Financing Cash Flow	$289.3M	↑ 728.57%

	FY21	Y/Y Change
Operating Cash Flow	$-128.9M	↓ 246.31%
Investing Cash Flow	$-99.8M	↓ 76.38%
Financing Cash Flow	$250.3M	↓ 13.48%

	FY22	Y/Y Change
Operating Cash Flow	$-153.1M	↑ 18.72%
Investing Cash Flow	$20.5M	↓ 120.55%
Financing Cash Flow	$153.0M	↓ 38.87%

	FY23	Y/Y Change
Operating Cash Flow	$-102.8M	↓ 32.83%
Investing Cash Flow	$139.9M	↑ 581.74%
Financing Cash Flow	$4.2M	↓ 97.26%

	FY24	Y/Y Change
Operating Cash Flow	$-194.5M	↑ 89.16%
Investing Cash Flow	$-404.1M	↓ 388.86%
Financing Cash Flow	$608.9M	↑ 14424.12%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-39.6M	↓ 592.12%
Investing Cash Flow	$-330.6M	↓ 1844.44%
Financing Cash Flow	$353.8M	↑ 18191.42%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-42.9M	↑ 8.45%
Investing Cash Flow	$15.6M	↓ 104.73%
Financing Cash Flow	$1.4M	↓ 99.6%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-50.2M	↑ 16.89%
Investing Cash Flow	$-157.7M	↓ 1108.06%
Financing Cash Flow	$250.9M	↑ 17670.4%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-61.8M	↑ 23.1%
Investing Cash Flow	$68.6M	↓ 143.49%
Financing Cash Flow	$2.8M	↓ 98.9%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-79.2M	↑ 28.11%
Investing Cash Flow	$48.6M	↓ 29.1%
Financing Cash Flow	$258.0K	↓ 90.67%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-59.9M	↓ 24.34%
Investing Cash Flow	$60.0M	↑ 23.46%
Financing Cash Flow	$245.7M	↑ 95142.64%

Kymera Therapeutics Technicals Summary

Sell

Neutral

Buy

Kymera Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Kymera Therapeutics Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Kymera Therapeutics Inc	-4.13%	36.51%	-11.09%	46.62%	32.17%
Regeneron Pharmaceuticals, Inc.	6.48%	-15.2%	-50.31%	-3.3%	-2.01%
Beone Medicines Ltd	1.77%	24.81%	62.78%	79.11%	29.69%
Vertex Pharmaceuticals Incorporated	-14.45%	-19.13%	-17.84%	34.68%	41.87%
Alnylam Pharmaceuticals, Inc.	13.79%	83.28%	75.87%	111.28%	242.25%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Kymera Therapeutics Inc	NA	NA	NA	-3.39	-0.33	-0.2	NA	13.77
Regeneron Pharmaceuticals, Inc.	14.6	14.6	1.2	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.73	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.86	27.86	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Kymera Therapeutics Inc	Buy	$3.0B	32.17%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$61.4B	-2.01%	14.6	31.37%
Beone Medicines Ltd	NA	$36.5B	29.69%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$100.5B	41.87%	27.86	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$59.5B	242.25%	NA	-12.96%

Kymera Therapeutics Dividend announcements

Kymera Therapeutics Earnings
Kymera Therapeutics’s price-to-earnings ratio stands at None

About Kymera Therapeutics Inc

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside of the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Organization	Kymera Therapeutics
Employees	218
CEO	Dr. Nello Mainolfi M.D., Ph.D.
Industry	Health Technology

Key Management of Kymera Therapeutics Inc

Name	Title
Dr. Bruce L. Booth DPHIL, Ph.D.	Co-Founder & Independent Chairman
Dr. Nello Mainolfi M.D., Ph.D.	Co-Founder, President, CEO & Director
Mr. Bruce N. Jacobs CFA	Chief Financial Officer
Dr. Jeremy G. Chadwick Ph.D.	Chief Operating Officer
Ms. Ellen V. Chiniara Esq., J.D.	Chief Legal Officer & Corporate Secretary
Dr. Jared A. Gollob M.D.	Chief Medical Officer
Ms. Justine E. Koenigsberg	Vice President of Investor Relations
Ms. Karen Weisbach	Head of People & Culture
Dr. Juliet Williams B.A Ph.D.	Head of Research
Mr. Noah Goodman M.B.A.	Chief Business Officer

Important FAQs about investing in KYMR Stock from India :

What is Kymera Therapeutics share price today?

Kymera Therapeutics share price today is $41.20 as on August 30, 2025 at 1:29 am IST at the close of the market. Kymera Therapeutics share today touched a day high of $42.02 and a low of $41.04.

What is the 52 week high and 52 week low for Kymera Therapeutics share?

Kymera Therapeutics share touched a 52 week high of $53.27 and a 52 week low of $19.45. Kymera Therapeutics stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $41.20, lower by 22.66% versus the 52 week high.

How to invest in Kymera Therapeutics Stock (KYMR) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Kymera Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Kymera Therapeutics Shares that will get you 0.0364 shares as per Kymera Therapeutics share price of $41.20 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Kymera Therapeutics Stock (KYMR) from India?

Indian investors can start investing in Kymera Therapeutics (KYMR) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Kymera Therapeutics stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Kymera Therapeutics share’s latest price of $41.20 as on August 30, 2025 at 1:29 am IST, you will get 0.2427 shares of Kymera Therapeutics. Learn more about fractional shares .

What are the returns that Kymera Therapeutics has given to Indian investors in the last 5 years?

Kymera Therapeutics stock has given 32.17% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?